EGFR and non-small cell lung carcinoma: The prospective study Impower150 included 124 chemotherapy-naive NSCLC patients with EGFR mutations, of which 91 patients with EGFR sensitive mutations were assigned to three different regimens: atezolizumab plus bevacizumab plus carboplatin plus paclitaxel (ABCP), bevacizumab plus carboplatin plus paclitaxel (BCP), and atezolizumab plus carboplatin plus paclitaxel (ACP).